Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee E, Padgett B. Altern Ther Health Med. 2021; 27(4):8–13.
No comparison group, so it cannot separate the treatment from placebo or natural recovery.
- Who or what was studied
- 17 patients with knee pain at one Florida clinic; 16 reached by phone
- Design
- Retrospective chart review with a follow-up phone survey
What it found
Of 16 patients contacted, 14 (87.5%) said their knee pain eased after an injection into the knee of BPC-157 alone (12 patients) or BPC-157 with thymosin beta-4 (4 patients).
What it doesn't show
No control group, no validated outcome measures, patients rated their own pain by phone, follow-up ranged from 6 to 12 months, and it comes from a single clinic. It cannot separate the peptide from placebo, natural recovery or other treatment, so it cannot support a recommendation.
Funding and conflicts of interest
No funding or conflict-of-interest statement appears in the PubMed record. Check the full text.
Summary written from the study's abstract and checked against PubMed on November 9, 2026. How we check studies. Educational information, not medical advice.
Related studies
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (Tewari et al., 2026)
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Mendias et al., 2026)
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi et al., 2025)
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., 2025)